|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Nicardipine#Warnings]] |
| {{Nicardipine}}
| |
| {{CMG}}; {{AE}}:{{AK}}
| |
| | |
| '''''For patient information about Nicardipine, click [[Nicardipine (patient information)|here]].'''''
| |
| | |
| ==WARNINGS AND PRECAUTIONS==
| |
| | |
| ===Excessive Pharmacodynamic Effects===
| |
| | |
| In administering nicardipine, close monitoring of blood pressure and heart rate is required. Nicardipine may occasionally produce symptomatic hypotension or tachycardia. Avoid systemic hypotension when administering the drug to patients who have sustained an acute cerebral infarction or hemorrhage.
| |
| | |
| ===Use in Patients with Angina===
| |
| | |
| Increases in frequency, duration, or severity of angina have been seen in chronic therapy with oral nicardipine. Induction or exacerbation of angina has been seen in less than 1% of coronary artery disease patients treated with Cardene I.V. The mechanism of this effect has not been established.
| |
| | |
| ===Use in Patients with Heart Failure===
| |
| | |
| Titrate slowly when using Cardene I.V. Premixed Injection, particularly in combination with a beta-blocker, in patients with heart failure or significant left ventricular dysfunction because of possible negative inotropic effects.
| |
| | |
| ===Use in Patients with Impaired Hepatic Function===
| |
| | |
| Since nicardipine is metabolized in the liver, consider lower dosages and closely monitor responses in patients with impaired liver function or reduced hepatic blood flow.
| |
| | |
| ===Use in Patients with Impaired Renal Function===
| |
| | |
| When Cardene I.V. was given to mild to moderate hypertensive patients with moderate renal impairment, a significantly lower systemic clearance and higher area under the curve (AUC) was observed. These results are consistent with those seen after oral administration of nicardipine. Titrate gradually in patients with renal impairment.
| |
| | |
| ===Intravenous Infusion Site===
| |
| | |
| To reduce the possibility of venous thrombosis, phlebitis, local irritation, swelling, extravasation, and the occurrence of vascular impairment, administer drug through large peripheral veins or central veins rather than arteries or small peripheral veins, such as those on the dorsum of the hand or wrist. To minimize the risk of peripheral venous irritation, change the site of the drug infusion every 12 hours.
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |